The European Commission has opened an investigation into Sanofi, suspecting the pharmaceutical giant of violating antitrust rules through a campaign that disparaged a rival influenza vaccine. The probe centers on Sanofi’s promotional tactics aimed at healthcare professionals in Germany and France, where the company holds a dominant market position.
Sanofi is accused of portraying the CSL Seqirus vaccine, Fluad, as less effective than its own Efluelda vaccine. This campaign reportedly challenged the established national vaccine recommendations in several European Union member states, raising concerns about the accuracy and fairness of Sanofi’s messaging.
Efluelda is specially formulated to provide enhanced protection against influenza for individuals over 60, a key demographic vulnerable to severe flu complications. Meanwhile, Fluad is the only competing vaccine recommended for these at-risk patients, making it critical that communications regarding both vaccines remain truthful and unbiased. The European Commission’s inquiry will examine whether Sanofi’s campaign misled healthcare providers by suggesting that the scientific evidence supporting Fluad was weaker than that for Efluelda.
This investigation highlights the broader regulatory scrutiny on pharmaceutical companies’ promotional activities, particularly when market dominance intersects with public health priorities. Ensuring that medical professionals receive clear and accurate information about available vaccines is vital for maintaining trust and effective immunization strategies.